U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C23H28ClN5O3
Molecular Weight 457.953
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of AZIMILIDE

SMILES

CN1CCN(CCCCN2C(=O)CN(\N=C\C3=CC=C(O3)C4=CC=C(Cl)C=C4)C2=O)CC1

InChI

InChIKey=MREBEPTUUMTTIA-PCLIKHOPSA-N
InChI=1S/C23H28ClN5O3/c1-26-12-14-27(15-13-26)10-2-3-11-28-22(30)17-29(23(28)31)25-16-20-8-9-21(32-20)18-4-6-19(24)7-5-18/h4-9,16H,2-3,10-15,17H2,1H3/b25-16+

HIDE SMILES / InChI

Description

Azimilide is a class III antiarrhythmic agent that prolongs cardiac repolarisation by blocking both the rapidly and slowly activating components of the delayed rectifier potassium channel. The most important consequence of this is apparent rate-independent activity, so that, unlike other class III antiarrhythmics, azimilide does not lose efficacy at high heart rates. Azimilide has very predictable pharmacokinetics, is predominantly hepatically metabolized, and has no significant drug interactions with digoxin or warfarin. The most common adverse effects reported by patients on azimilide were approximately equal in frequency with those on placebo: headache, asthenia, infection, diarrhea and dizziness. Azimilide is in phase III clinical trials for the treatment both supraventricular and ventricular tachyarrhythmias.

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
610.0 nM [IC50]

PubMed

Sample Use Guides

In Vivo Use Guide
100 and 125 mg once daily
Route of Administration: Oral